Shr-8068
Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 65/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the Advanced Non-small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ono-4538 Ono Pharmaceutical Co., Ltd. | Phase 3 | BB |
Shr-A1811 Sun Yat-sen University | Phase 3 | BB |
bay2927088 Bayer | Phase 1/2 | BB |
Ucpvax Centre Hospitalier Universitaire de Besancon | Phase 2 | BB |
Cimetidine Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 3 | B |
View all 30 →
Same molecule, other indications
Shr-8068 is also rated in:
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →